Asimov and AGC Biologics struck a licensing deal to deploy Asimov’s LV Edge Packaging cell line at AGC’s Milan Cell & Gene Center of Excellence. The LV Edge system uses an engineered HEK293 line with inducible viral genes and enables one‑plasmid transfection instead of the standard four‑plasmid process, reducing GMP plasmid requirements, process complexity and supply‑chain risk. AGC validated the system with clinically relevant genes and will offer the packaging service to customers worldwide. The agreement addresses manufacturing bottlenecks for lentiviral vectors by lowering plasmid overhead and streamlining transfection, a pragmatic step to scale cell and gene therapy supply chains.